The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://zubairrtlv274223.eqnextwiki.com/5440102/retatrutide_vs_tirzepatide_a_comparative_analysis